LYRA LANTERN PHASE 2 STUDY RESULTS FOR LYR-210 IN CRS
Results of the LANTERN Phase 2 randomized controlled study evaluating the safety and efficacy of LYR-210 in chronic rhinosinusitis (CRS) were presented at Combined Otolaryngology Spring Meetings (COSM) 2021, by Anders Cervin of the University of Queensland, Australia, a key LANTERN investigator.
Additional LYR-210 six-month long-term data and PK data were presented at the American Rhinologic Society (ARS) Annual Meeting in October 2021.
Additional, new data from the LANTERN Phase 2 study of LYR-210 in chronic rhinosinusitis were presented at Combined Otolaryngology Spring Meetings (COSM) 2022, by Anders Cervin of the University of Queensland, Australia, a key LANTERN investigator.
